Navigation Links
The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
Date:5/18/2009

DOYLESTOWN, Pa., May 18 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced an update on the Company's possible alternative strategies going forward following the Company's recent announcement regarding the unexpected positive finding for its QR-333 (Diabetic Peripheral Neuropathy) compound during the recently completed Phase 11b clinical trial. While the complete statistical results of the trial are awaited, the Company's Board of Directors and management will immediately initiate a process to explore and evaluate various strategic and financial alternatives available, with the goal to maximize stockholder value.

The possible options being considered by the Company currently include, licensing, joint venture, and if beneficial to the stockholders, the sale of the Pharma division. In addition, the Company will be actively considering the separation of the OTC and Pharma assets to further explore all means of maximizing stockholder value. In order to properly evaluate these options, the Company is in the process of retaining a nationally recognized investment banker to serve as its financial advisor in connection with this process.

The Company also confirmed today that in addition to the consolidation process currently underway at its manufacturing facility, Quigley Manufacturing Inc., it is committed to implementing further cost reductions particularly in the area of compensation for certain executives and other operating areas as deemed necessary. The cost reduction has become necessary due to reduced performance of the Company's OTC segment of the business which is reflective of the broad downturn in consumer spending on this category of goods.

Guy J. Quigley, Chairman, Chief Executive Officer and President of The Quigley Corporation, stated, "As we
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
2. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
3. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
4. The Quigley Corporation Reports First Quarter 2009 Results
5. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
6. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
7. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
8. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
9. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
10. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
11. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... TX (PRWEB) October 30, 2014 ... released today its 2014 third quarter infection rates ... Texas boasted infection rates of only two percent ... patient satisfaction scores exceeding 98 percent. , “We ... quarter, which included rising satisfaction scores,” said Robert ...
(Date:10/30/2014)... News) -- Scientists who used stem cells to create ... could provide a new way to learn more about ... team used human pluripotent stem cells -- which can ... to grow the functional miniature stomachs, to study infection ... of ulcers and stomach cancer. The miniature stomachs ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Many U.S. colleges ... even though tanning increases the risk for skin ... young adults, particularly white women, so colleges should ... the researchers said. "Public health efforts are ... awareness of the harms that indoor tanning poses ...
(Date:10/30/2014)... A new vaccine that could help prevent some cases ... U.S. Food and Drug Administration on Wednesday. Trumenba ... 10 and 25 from invasive meningococcal disease caused by ... bacteria can infect the bloodstream (sepsis) and the lining ... a leading cause of bacterial meningitis, and infection can ...
(Date:10/29/2014)... and even non-invasive technologies is increasing in the medical ... out a range of operative procedures using keyhole surgery ... scars as a result. Similar opportunities are now becoming ... – instead of using injections or probes to deliver ... them via a plaster which continuously, gently and painlessly ...
Breaking Medicine News(10 mins):Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Gentle caffeine boost for premature babies 2
... ... ... company that launched the first FDA cleared Fourier/spectral domain OCT in the US, announced its ... , ,“Following our 19% revenue growth in 2009 over 2008, we expected the economy and ...
... Emergency services double ... ... announced ambitious plans to add a second inpatient tower to meet what has become an enormous ... beds, more emergency care and more jobs to the Anschutz Medical Campus and the state., , ...
... ... inspire, motivate and empower members of the healthcare team and the patients and family members ... calling for entries now, with winners announced later this year. , ... Rockville, MD (PRWEB) May 24, 2010 -- Dorland ...
... PLoS ONE, Massachusetts General Hospital (MGH) ... individuals unconsciously distribute their preferences regarding approaching or ... appear to meet the strict criteria used to ... if confirmed in future studies, could potentially be ...
... patients with transformed lymphoma showed "remarkable" response to lenalidomide, ... international study, involving 24 medical centers in the United ... Society of Clinical Oncology ( http://www.asco.org/ ) annual meeting ... of patients with transformed lymphoma treated with lenalidomide responded ...
... triggers the need for a night,s rest may be the ... Brain injuries can disrupt the body,s production of the hormone ... , "We,ve known that people often have problems with sleep ... the exact causes of these problems," study author Shantha Rajaratnam ...
Cached Medicine News:Health News:Optovue Q1 2010 Revenue Up 57% Over Same Quarter 2009 2Health News:,University of Colorado Hospital Moving Forward with $400 Million Expansion, 2Health News:,University of Colorado Hospital Moving Forward with $400 Million Expansion, 3Health News:Dorland Health Announces People Awards Honoring Excellence & Dedication Among Healthcare Professionals - Call For Entries 2Health News:Study finds 'law-like' patterns in human preference behavior 2Health News:Study finds 'law-like' patterns in human preference behavior 3Health News:Study identifies promising treatment for aggressive lymphoma 2Health News:Brain Injuries May Lead to Sleep Woes 2
(Date:10/30/2014)... 2014 Molecular Profiles Ltd., a subsidiary of ... Maryland -based Xceleron have announced a ... clinical development that will be launched at AAPS in ... This partnership extends Molecular Profiles, new ROADMAP to ... this month. The company also has complementary collaborations in ...
(Date:10/30/2014)... 30, 2014  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced an upcoming presentation ... candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind ... given by Sant P. Chawla , M.D., ... principal investigator of the Company,s ongoing global, pivotal ...
(Date:10/30/2014)... October 30, 2014 , ... LGG contribuye a adquirir tolerancia a la proteína ... la proteína de la leche de la vaca (APLV) ... infancia. Hasta ahora, la APLV se trataba eliminando ... ha demostrado que es posible adquirir tolerancia oral ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today reported ... Total revenue was $2.4 million and $5.5 million for the three ... $2.5 million for the same periods in 2010. Total ... 2011, were $7.6 million and $15.0 million as compared to $6.1 ...
... 2011 CORRECTED -- Bionovo, Inc. (NASDAQ: BNVI ... the three months ended June 30, 2011. ... drug candidate, MF101, or Menerba™, during the past quarter, delivering ... and Chief Executive Officer. "We have completed the tasks which ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 9Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 10Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 11CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 2CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 3CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 4CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 5
... Ankle Orthosis enables the clinician to ... ankle joint to control muscle imbalance ... a pair of bilateral turnbuckles, controlling ... Simply adjust the turnbuckle to gradually ...
... Protection,Protects the heel while maintaining the ankle ... contact with a soft, cushioning AliPlast™ foam ... and liner cradles the heel in a ... change position freely in bed from side-lying ...
... Pediatric Ankle Cryo/Cuff is specifically designed to ... Using a combination of controlled compression and ... pain. The Pediatric Ankle Cryo/Cuff is ideal ... episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff is ...
SCD Sequential Compression System Intermittent Pneumatic Compression...
Medicine Products: